Safety and efficacy of BAY 94–9027, an extended-half-life factor VIII, during minor surgical procedures in patients with severe haemophilia A

Elena Santagostino, Shadan Lalezari, Mark T. Reding, Jonathan Ducore, Heng Joo Ng, Lone H. Poulsen, Lisa A. Michaels, Camila Linardi

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)e559-e562
JournalHaemophilia
Volume27
Issue number4
DOIs
StatePublished - Jul 2021

Keywords

  • clinical outcome
  • clinical trials
  • extended half-life
  • factor VIII
  • haemophilia A
  • minor surgery
  • PEGylation

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)

Cite this